Market revenue in 2021 | USD 35.4 million |
Market revenue in 2032 | USD 85.6 million |
Growth rate | 8.4% (CAGR from 2021 to 2032) |
Largest segment | Monoclonal antibodies |
Fastest growing segment | Thymectomy |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 64.41% in 2021. Horizon Databook has segmented the Russia myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
The Russian Federation in association with the U.S. officials is working toward improving healthcare practices of medical practitioners and hospitals in Russia. Such initiatives are expected to support and improve access to a better healthcare system for patients suffering from MG in the country.
In addition, several reforms by Russian government, such as regulating pharmaceutical prices & production as well as decentralizing the national budget to regional & local levels to reduce financial strain, are expected to increase treatment rate of MG in the country.
For instance, in April 2019, Generium Pharmaceutical, a Russia-based drug manufacturer, received Russian marketing permission for its biosimilar eculizumab, one of the most expensive orphan drugs in Russia.
Horizon Databook provides a detailed overview of country-level data and insights on the Russia myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Russia myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account